Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

Arda Can Cetindag; Carola G. Schipke; Hermann Esselmann; Niels Kruse; Jens Wiltfang; Anja Schneider; Klaus Fliessbach; Carolin Miklitz; Franziska Maier; Katharina Buerger; Daniel Janowitz; Michael Ewers; Sophia Stöcklein; Robert Perneczky; Boris-Stephan Rauchmann; Carolin Kurz; Stefan Teipel; Ingo Kilimann; Doreen Goerss; Christoph Laske; Sebastian Sodenkamp; Elham Najafpour; Michael Wagner; Sandra Roeske; Ingo Frommann; Melina Stark; Frederic Brosseron; Alfredo Ramirez; Luca Kleineidam; Josef Priller; Eike Jakob Spruth; Maria Gemenetzi; Slawek Altenstein; Emrah Düzel; Wenzel Glanz; Enise I. Incesoy; Michaela Butryn; Chris Bauer; Frank Jessen; Oliver Peters

doi:10.1016/j.tjpad.2026.100544

March 28, 2026The Journal of Prevention of Alzheimer s DiseaseOpen Access

Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness of plasma GFAP compared to CSF GFAP in detecting amyloid pathology and predicting clinical progression in early Alzheimer's disease.
Comparison of plasma GFAP and CSF GFAP levels in early Alzheimer's disease patients.
Assessment of diagnostic relevance for amyloid detection.
Analysis of prognostic significance for clinical progression.
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology.
Increased plasma GFAP levels are associated with higher risk of clinical progression in patients.
Results indicate plasma GFAP is a sensitive and minimally invasive biomarker.

Implication

Findings demonstrate plasma GFAP detects amyloid pathology in early Alzheimer's, suggesting improved diagnosis and monitoring.

Abstract

Plasma GFAP is a sensitive, minimally invasive biomarker with diagnostic relevance for amyloid detection and prognostic relevance for clinical progression in early AD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cetindag et al. (2026) studied this question.

synapsesocial.com/papers/69ccb55116edfba7beb8748f https://doi.org/10.1016/j.tjpad.2026.100544

View Full Paper

Ask AI

Bookmark

Share

Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

Key Points

Implication

Abstract

Discussion

Cite This Study

Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from The Journal of Prevention of Alzheimer s Disease

Keep reading

More related papers

More from The Journal of Prevention of Alzheimer s Disease